These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 33745105)
1. Adherence to hydroxyurea, health-related quality of life domains and attitudes towards a smartphone app among Irish adolescents and young adults with sickle cell disease. Fogarty H; Gaul A; Syed S; Aleksejenko N; Geoghegan R; Conroy H; Crampton E; Ngwenya N; Tuohy E; McMahon C Ir J Med Sci; 2022 Apr; 191(2):809-816. PubMed ID: 33745105 [TBL] [Abstract][Full Text] [Related]
2. Technology Access and Smartphone App Preferences for Medication Adherence in Adolescents and Young Adults With Sickle Cell Disease. Badawy SM; Thompson AA; Liem RI Pediatr Blood Cancer; 2016 May; 63(5):848-52. PubMed ID: 26844685 [TBL] [Abstract][Full Text] [Related]
3. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach. Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683 [TBL] [Abstract][Full Text] [Related]
4. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417 [TBL] [Abstract][Full Text] [Related]
5. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease. Badawy SM; Thompson AA; Penedo FJ; Lai JS; Rychlik K; Liem RI Eur J Haematol; 2017 Jun; 98(6):608-614. PubMed ID: 28306171 [TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896936 [TBL] [Abstract][Full Text] [Related]
7. Beliefs about hydroxyurea in youth with sickle cell disease. Badawy SM; Thompson AA; Liem RI Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):142-148. PubMed ID: 29397333 [TBL] [Abstract][Full Text] [Related]
8. Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents. Reddy PS; Cai SW; Barrera L; King K; Badawy SM Ann Med; 2022 Dec; 54(1):683-693. PubMed ID: 35234095 [TBL] [Abstract][Full Text] [Related]
9. Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review. Yang M; Elmuti L; Badawy SM Biomed Res Int; 2022; 2022():2122056. PubMed ID: 35898672 [TBL] [Abstract][Full Text] [Related]
10. Feasibility of a clinic-based, multicomponent hydroxyurea adherence intervention for adolescents and young adults with sickle cell disease. Murphy BN; Keenan-Pfeiffer ME; Lane A; Crosby LE; Walsh KE Pediatr Blood Cancer; 2024 Sep; 71(9):e31144. PubMed ID: 38884218 [TBL] [Abstract][Full Text] [Related]
11. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study. Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291 [TBL] [Abstract][Full Text] [Related]
12. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease. Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779 [TBL] [Abstract][Full Text] [Related]
13. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol. Smaldone A; Manwani D; Aygun B; Smith-Whitley K; Jia H; Bruzzese JM; Findley S; Massei J; Green NS BMC Pediatr; 2019 Oct; 19(1):354. PubMed ID: 31615480 [TBL] [Abstract][Full Text] [Related]
14. Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study. Namaganda P; Nantume P; Mubiru KR; Twimukye A; Wiltshire CS BMC Health Serv Res; 2024 May; 24(1):666. PubMed ID: 38802815 [TBL] [Abstract][Full Text] [Related]
15. Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease. Badawy SM; Thompson AA; Holl JL; Penedo FJ; Liem RI Pediatr Hematol Oncol; 2018; 35(5-6):297-308. PubMed ID: 30636474 [TBL] [Abstract][Full Text] [Related]
16. Improving Medication Adherence with Two-way Short Message Service Reminders in Sickle Cell Disease and Asthma. A feasibility randomized controlled trial. Pernell BM; DeBaun MR; Becker K; Rodeghier M; Bryant V; Cronin RM Appl Clin Inform; 2017 May; 8(2):541-559. PubMed ID: 28536723 [TBL] [Abstract][Full Text] [Related]
17. Adherence to Hydroxyurea and Patients' Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study. Madkhali MA; Abusageah F; Hakami F; Zogel B; Hakami KM; Alfaifi S; Alhazmi E; Zaalah S; Trabi S; Alhazmi AH; Mohrag M; Malhan H Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256385 [No Abstract] [Full Text] [Related]
18. Allocation of Treatment Responsibility and Adherence to Hydroxyurea Among Adolescents With Sickle Cell Disease. Creary SE; Modi AC; Stanek JR; Chisolm DJ; O'Brien SH; Nwankwo C; Crosby LE J Pediatr Psychol; 2019 Nov; 44(10):1196-1204. PubMed ID: 31403687 [TBL] [Abstract][Full Text] [Related]
19. Study protocol for ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness): Using small business partnerships to deliver a scalable and novel hydroxyurea adherence solution to youth with sickle cell disease. Walden J; Brown L; Seiguer S; Munshaw K; Rausch J; Badawy S; McGann P; Winkler S; Gonzalez L; Creary S PLoS One; 2024; 19(6):e0304644. PubMed ID: 38917111 [TBL] [Abstract][Full Text] [Related]
20. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease. Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]